


- \*\*SUSPENDED\*\* ALLIANCE A011104** Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer (**Feig**)
- \*\*SUSPENDED\*\* UCI 11-21** Analysis of Imaging Features of Breast Diseases and Breast Density Evaluated on Mammogram, Ultrasound & MRI Collected in a database (**Su**)
- UCI 15-83** Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting (**Tromberg**)
- UCI 11-15** Correlation of Clinical and MRI Findings with Prognosis of Breast Cancer Patients (**Su**)
- UCI 14-86** Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System (**Su**)
- UCI 16-23** Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer [The WISDOM Study (Women Informed to Screen Depending On Measures of Risk)] (**Anton-Culver**)

SCREENING / DIAGNOSTIC / EPIDEMIOLOGIC / INTERVENTIONAL

**BREAST CANCER**

CORRELATIVE / OBSERVATIONAL

- UCI 95-29** Measurement of Breast Tissue Optical Properties (**Tromberg**)
- UCI 10-24** ATHENA Breast Health Network (**Anton-Culver**)
- UCI 13-19** Registry Study of Patients Treated with Neoadjuvant Chemotherapy Followed by Mastectomy in Stage I, II, III BREAST CANCER (**Daroui**)
- UCI 14-81** Mi Salud, Mi Vida: A Self-Discovery Tool for Latina Breast Cancer Survivors (**Sorkin**)
- UCI 16-01** Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) (**Nelson**)
- UCI 15-64** A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-Conserving Surgery (**Lin**)
- UCI 17-43** Blood Collection Protocol for Circulating Tumor Cells, Circulating Cancer Associated Fibroblasts and Tissue Factor in Breast Cancer Patients (**Parajuli**)



## BREAST CANCER

### Multiple Disease Site

**UCI 17-90** A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy **(Ou)**

**UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors **(Ou)**

**UCI 16-74** A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine **(Carrillo)**

### Locally Advance / Metastatic

**SWOG S1609** DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors **(Bota)**

**ECOG EAY131** Molecular Analysis for Therapy Choice (MATCH) **(Bota)**

**NRG BR002** A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer **(Daroui)**

**UCI 17-79** Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer **(Parajuli)**

**UCI 18-06** A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment **(Parajuli)**